Potential Molecular Targets of α-Linolenic Acid from Green Purslane (Portulaca oleracea) Through SwissTargetPrediction Analysis
DOI:
https://doi.org/10.30872/jtpc.v10i1.376Keywords:
α-Linolenic acid, Portulaca oleracea, In silico study, SwissTargetPrediction, Molecular Target PredictionAbstract
α-Linolenic acid is an essential omega-3 fatty acid widely found in medicinal plants, including Portulaca oleracea, and is known for its diverse pharmacological activities. However, the molecular targets underlying its biological effects remain insufficiently explored. This study aimed to predict the potential molecular targets of α-linolenic acid using an in silico approach. The molecular structure of α-linolenic acid was obtained in the form of SMILES from PubChem, followed by target prediction using SwissTargetPrediction. The analysis revealed several key targets, including peroxisome proliferator-activated receptors (PPARG, PPARD, and PPARA), fatty acid binding proteins (FABP4 and FABP3), free fatty acid receptor 1 (FFAR1), and cyclooxygenase-1 (PTGS1). These targets are primarily associated with lipid metabolism, glucose regulation, and inflammatory pathways. The results indicate that α-linolenic acid exhibits a multi-target mechanism of action, suggesting its potential as an antidiabetic, anti-inflammatory, and cardioprotective agent. This study provides valuable insights into the molecular basis of α-linolenic acid activity and highlights its potential for further development in pharmacological applications.
Downloads
References
[1] Zhang Y, Li X, Wang Z, et al. Natural products in drug discovery: advances and opportunities. Pharmacol Res. 2022;178:106154.
[2] Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: recent advances and future perspectives. Biotechnol Adv. 2022;60:108048.
[3] Seca AML, Pinto DCGA. Plant secondary metabolites as anticancer agents: recent studies. Int J Mol Sci. 2022;23(3):1242.
[4] Zhou Y, Xin H, Rahman K, et al. Portulaca oleracea L.: A review of phytochemistry and pharmacological effects. Biomed Pharmacother. 2022;148:112762.
[5] Iranshahy M, Javadi B, Iranshahi M, et al. A review of traditional uses, phytochemistry and pharmacology of Portulaca oleracea L. J Ethnopharmacol. 2023;303:115938.
[6] Alam MA, Juraimi AS, Rafii MY, et al. Nutritional and medicinal properties of purslane (Portulaca oleracea L.): a review. J Food Compos Anal. 2022;103:104233.
[7] Uddin MK, Juraimi AS, Ali ME, Ismail MR. Evaluation of antioxidant properties of Portulaca oleracea. Food Chem. 2022;372:131246.
[8] Wang L, Li Q, Liu Y, et al. Bioactive compounds and pharmacological properties of Portulaca oleracea. Molecules. 2023;28(5):2104.
[9] Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans. 2022;50(3):1231–1245.
[10] Baker EJ, Miles EA, Burdge GC, et al. Metabolism and functional effects of plant-derived omega-3 fatty acids. Prog Lipid Res. 2022;85:101139.
[11] Swanson D, Block R, Mousa SA. Omega-3 fatty acids EPA and DHA: health benefits. Adv Nutr. 2022;13(1):112–126.
[12] Rajaram S. Health benefits of plant-derived α-linolenic acid. Nutrients. 2022;14(3):567.
[13] Li J, Guasch-Ferré M, Chung W, et al. Associations of dietary omega-3 fatty acids with cardiovascular disease. J Am Coll Cardiol. 2022;79(5):512–525.
[14] Zhao G, Etherton TD, Martin KR, et al. Anti-inflammatory effects of polyunsaturated fatty acids. Am J Clin Nutr. 2022;115(2):450–460.
[15] Bäck M, Yurdagul A, Tabas I, et al. Inflammation and its resolution in atherosclerosis. Nat Rev Cardiol. 2022;19(7):423–437.
[16] Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease. Nat Med. 2022;28(6):1123–1136.
[17] Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence. Diabetes Res Clin Pract. 2023;200:110789.
[18] Yaribeygi H, Atkin SL, Simental-Mendía LE, et al. Molecular mechanisms of oxidative stress in diabetes mellitus. Oxid Med Cell Longev. 2022;2022:1–13.
[19] Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features. Nucleic Acids Res. 2022;50(W1):W357–W364.
[20] Gfeller D, Grosdidier A, Wirth M, et al. Computational target prediction of bioactive molecules. Bioinformatics. 2022;38(10):2875–2882.
[21] Lagunin AA, Dubovskaja VI, Rudik AV, et al. PASS prediction of activity spectra for biologically active substances. Bioinformatics. 2022;38(7):1939–1945.
[22] Filimonov DA, Lagunin AA, Gloriozova TA, et al. Prediction of biological activity spectra using PASS online. Chem Heterocycl Compd. 2023;59(2):89–97.
[23] Sliwoski G, Kothiwale S, Meiler J, Lowe EW. Computational methods in drug discovery. Pharmacol Rev. 2022;74(3):492–520.
[24] Ekins S, Puhl AC, Zorn KM, et al. Exploiting machine learning for drug discovery. Nat Rev Drug Discov. 2023;22(2):115–135.
[25] van Norman GA. Limitations of animal studies and the importance of computational approaches. JACC Basic Transl Sci. 2022;7(1):1–15.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Fendy Prasetyawan, M Wahyu Ariawan, Yuneka Saristiana, Novynanda Salmasfattah, Lisa Savitri (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
